Clinical Trials in Wahroonga, New South Wales
17 recruiting
Showing 1–16 of 16 trials
Recruiting
Phase 2
Working Out M0 Bipolar Androgen Therapy
Prostate Cancer
Australian and New Zealand Urogenital and Prostate Cancer Trials Group69 enrolled12 locationsNCT06594926
Recruiting
Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Prostate Cancer
Astellas Pharma Global Development, Inc.900 enrolled241 locationsNCT02960022
Recruiting
Phase 3
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
Prostate CancerCryotherapyProstate Cancer Recurrent+3 more
Clarity Pharmaceuticals Ltd220 enrolled28 locationsNCT06970847
Recruiting
Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation
Relay Therapeutics, Inc.540 enrolled120 locationsNCT06982521
Recruiting
Phase 1
Study to Assess the Safety and Pharmacokinetics of AVD275 Injection in Patients With Osteoarthritis of the Knee
Avidence Therapeutics15 enrolled1 locationNCT07338266
Recruiting
Phase 3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled253 locationsNCT07028853
Recruiting
Phase 1
Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy
Lumbosacral RadiculopathySciaticaSciatic Radiculopathy+3 more
Consano Bio24 enrolled3 locationsNCT07264270
Recruiting
Phase 1
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
PYC Therapeutics116 enrolled9 locationsNCT06714006
Recruiting
Not Applicable
Akyva First In Human
Underactive Bladder
Iota Biosciences, Inc15 enrolled2 locationsNCT06956209
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled279 locationsNCT06764485
Recruiting
Phase 1Phase 2
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled100 locationsNCT04752722
Recruiting
Phase 1
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Metastatic Prostate Cancer
ORIC Pharmaceuticals250 enrolled27 locationsNCT05413421
Recruiting
Phase 3
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Germ Cell Tumor
University of Sydney500 enrolled28 locationsNCT02582697
Recruiting
Not Applicable
Novel Treatment Delivery of ECAP-controlled Closed-loop SCS for Chronic Pain
Chronic Pain
Saluda Medical Pty Ltd200 enrolled23 locationsNCT04662905
Recruiting
Phase 2
ASCEND: A Clinical Trial to Evaluate the Safety and Effectiveness of VIA Disc NP, a Supplement for Degenerated Intervertebral Discs
Degenerative Disc DiseaseDisc DegenerationLumbar Discogenic Pain
VIVEX Biologics, Inc.110 enrolled5 locationsNCT06615505
Recruiting
Phase 2
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
Prostatic Neoplasms, Castration-Resistant
Leiden University Medical Center168 enrolled19 locationsNCT05393791